User login
Key clinical point: In a real-world cohort of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) monotherapy, the 4-year overall survival (OS) was nearly 18%.
Major finding: The mean progression-free survival (PFS) was 3.4 months and OS was 13.0 months. The 4-year OS rate was 17.9%. The predictors of favorable OS and PFS included age >70 years, a good Eastern Cooperative Oncology Group Performance Status score, programmed cell death-ligand 1 tumor proportion score of ≥50%, absence of bone metastasis, and presence of immune-related skin toxicity.
Study details: The data come from a real-world retrospective cohort study of 435 patients diagnosed with advanced, metastatic, or recurrent NSCLC and treated with ICI monotherapy across seven Japanese centers (2015-2018).
Disclosures: No information on funding and disclosures was available.
Source: Yoneda T et al. Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. Clin Lung Cancer. 2022 (May 1). Doi: 10.1016/j.cllc.2022.03.008
Key clinical point: In a real-world cohort of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) monotherapy, the 4-year overall survival (OS) was nearly 18%.
Major finding: The mean progression-free survival (PFS) was 3.4 months and OS was 13.0 months. The 4-year OS rate was 17.9%. The predictors of favorable OS and PFS included age >70 years, a good Eastern Cooperative Oncology Group Performance Status score, programmed cell death-ligand 1 tumor proportion score of ≥50%, absence of bone metastasis, and presence of immune-related skin toxicity.
Study details: The data come from a real-world retrospective cohort study of 435 patients diagnosed with advanced, metastatic, or recurrent NSCLC and treated with ICI monotherapy across seven Japanese centers (2015-2018).
Disclosures: No information on funding and disclosures was available.
Source: Yoneda T et al. Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. Clin Lung Cancer. 2022 (May 1). Doi: 10.1016/j.cllc.2022.03.008
Key clinical point: In a real-world cohort of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) monotherapy, the 4-year overall survival (OS) was nearly 18%.
Major finding: The mean progression-free survival (PFS) was 3.4 months and OS was 13.0 months. The 4-year OS rate was 17.9%. The predictors of favorable OS and PFS included age >70 years, a good Eastern Cooperative Oncology Group Performance Status score, programmed cell death-ligand 1 tumor proportion score of ≥50%, absence of bone metastasis, and presence of immune-related skin toxicity.
Study details: The data come from a real-world retrospective cohort study of 435 patients diagnosed with advanced, metastatic, or recurrent NSCLC and treated with ICI monotherapy across seven Japanese centers (2015-2018).
Disclosures: No information on funding and disclosures was available.
Source: Yoneda T et al. Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. Clin Lung Cancer. 2022 (May 1). Doi: 10.1016/j.cllc.2022.03.008